Effect of human papillomavirus vaccination on cervical cancer screening in Alberta

CMAJ

Volumn 188, Issue 12, 2016, Pages E281-E288

  Kim, Jong ^a   Bell, Christopher ^b   Sun, Maggie ^c   Kliewer, Gordon ^c   Xu, Linan ^c   McInerney, Maria ^c   Svenson, Lawrence W ^a,b,d   Yang, Huiming ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b Surveillance and Assessment   (Canada)

^c ALBERTA HEALTH SERVICES   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTION; RISK ASSESSMENT; RISK REDUCTION; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; YOUNG ADULT; ADOLESCENT; ALBERTA; EARLY CANCER DIAGNOSIS; FACTUAL DATABASE; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR; VIROLOGY;

ADOLESCENT; ALBERTA; CASE-CONTROL STUDIES; DATABASES, FACTUAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LOGISTIC MODELS; MASS SCREENING; PAPANICOLAOU TEST; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VAGINAL SMEARS; YOUNG ADULT;

EID: 84987817225     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.151528     Document Type: Article

References (36)

1. Lenhard RE, Osteen RT, Gansler T,editors. Clinical oncology. Atlanta: The American Cancer Society; 2001.
2. Organized cancer screening in Alberta 2015. Calgary: Alberta Health Services; 2015. Available: www.screeningforlife.ca/images/reports/Organized-Cancer-Screening-in-Alberta-2015-Report.pdf (accessed 2015 Nov. 10).
3. Crum CP, Abbott DW, Quade BJ. Cervical cancer screening: from the Papanicolaou smear to the vaccine era. J Clin Oncol 2003;21(Suppl 10):224s-30s.
4. Miller AB, Gribble S, Nadeau C, et al. Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) - Human papillomavirus and cervical components. J Cancer Policy 2015;4:1-6.
5. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
6. Crowe E, Pandeya N, Brotherton JM, et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014;348:g1458.
7. Gertig DM, Brotherton JM, Budd AC, et al. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013;11:227.
8. Pollock KG, Kavanagh K, Potts A, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014;111:1824-30.
9. Smith LM, Strumpf EC, Kaufman JS, et al. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts. Pediatrics 2015;135:e1131-40.
10. Hariri S, Johnson ML, Bennett NM, et al. Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States. Cancer 2015;121:2775-81.
11. Hariri S, Bennett NM, Niccolai LM, et al. Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012. Vaccine 2015;33:1608-13.
12. Canada communicable disease report. Update on human papillomavirus (HPV) vaccines. An Advisory Committee Statement (ACS). Ottawa: Public Health Agency of Canada; 2012. Available: www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/assets/pdf/12vol-38-acs-dcc-1-eng.pdf (accessed 2015 Dec. 21).
13. Alberta HT. Impact of HPV immunization on infection prevalence. Edmonton: Government of Alberta; 2015. Available: www.health.alberta.ca/documents/HTA-2015-05-05-HPV-Prevalence.pdf (accessed 2015 Sept. 24).
14. Canadian immunization guide: part 4: active vaccines - human papillomavirus vaccine. Ottawa: Public Health Agency of Canada; 2015. Available: www.phac-aspc.gc.ca/publicat/cig-gci/p04-hpv-vph-eng.php (accessed 2015 Dec. 21).
15. Cervical cancer: about HPV and the HPV vaccine. Calgary: Alberta Health Services; 2012. Available: www.screeningforlife.ca/cervicalscreening/about-hpv-a-hpv-vaccine (accessed 2015 Nov. 30).
16. Guideline for screening for cervical cancer - Toward Optimized Practice (TOP) program. Edmonton: Toward Optimized Practice Program; 2015. Available: www.topalbertadoctors.org/download/587/cervical%20cancer%20guideline.pdf?-20150924145630 (accessed 2015 Sept. 23).
17. Alberta health care insurance plan statistical supplement. Edmonton: Alberta Government; 2014. Available: www.health.alberta.ca/documents/AHCIP-Stats-Supplement-14.pdf (accessed 2015 Nov. 19).
18. Person directory (PD). Edmonton: Alberta Netcare Learning Centre. Available: www.albertanetcare.ca/LearningCentre/Person-Directory.htm (accessed 2015 Dec. 17).
19. Alberta Health Services Immunization Program. 2013-2014 school immunization coverage rate. Edmonton: Alberta Health Services; 2014.
20. Liu XC, Bell CA, Simmonds KA, et al. HPV vaccine utilization, Alberta 2008/09-2013/14 school year. BMC Infect Dis 2016;16:15.
21. Overview of administrative health datasets. Edmonton: Government of Alberta; 2015. Available: www.health.alberta.ca/documents/Research-Health-Datasets.pdf (accessed 2016 Feb. 20).
22. Programmatic guidelines for screening for cancer of the cervix in Canada. Ottawa: Health Canada; 1998. Available: www.phac-aspc.gc.ca/cd-mc/pdf/screening.pdf (accessed 2015 Sept. 23).
23. Zhao FH, Hu SY, Bian JJ, et al. Comparison of ThinPrep and SurePath liquid-based cytology and subsequent human papillomavirus DNA testing in China. Cancer Cytopathol 2011;119:387-94.
24. Wright PK, Marshall J, Desai M. Comparison of SurePath and ThinPrep liquid-based cervical cytology using positive predictive value, atypical predictive value and total predictive value as performance indicators. Cytopathology 2010;21:374-8.
25. Serrano B, Alemany L, Tous S, et al. Potential impact of a ninevalent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7:38.
26. Chesson HW, Flagg EW, Koutsky L, et al. Modeling the impact of quadrivalent HPV vaccination on the incidence of Pap test abnormalities in the United States. Vaccine 2013;31:3019-24.
27. Malik T, Reimer J, Gumel A, et al. The impact of an imperfect vaccine and pap cytology screening on the transmission of human papillomavirus and occurrence of associated cervical dysplasia and cancer. Math Biosci Eng 2013;10:1173-205.
28. Moyer VA; U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;156(12):880-91, W312.
29. Ault KA, Joura EA, Kjaer SK, et al. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer 2011;128:1344-53.
30. Update on the recommended human papillomavirus (HPV) vaccine immunization schedule. Ottawa: Public Health Agency of Canada; 2015. Available: http://publications.gc.ca/collections/collection-2015/aspc-phac/HP40-128-2014-eng.pdf (accessed 2015 Oct. 6).
31. Evidence based recommendations on human papilloma virus (HPV) vaccines schedules: background paper for SAGE discussions. Geneva: World Health Organization; 2014. Available: www.who.int/immunization/sage/meetings/2014/april/1-HPV-Evidence-based-recommendationsWHO-with-Appendices2-3.pdf (accessed 2015 Oct. 6).
32. Siegrist CA. Vaccine immunology. In: Plotkin SA, editor. Vaccines. Elsevier; 2012. Available: www.who.int/immunization/documents/Elsevier-Vaccine-immunology/en/ (accessed 2015 Nov. 20).
33. Brothertona JM, Malloy M, Budd AC, et al. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: observational cohort of young women in Australia. Papillomavirus Res 2015;1:59-73.
34. Notifiable sexually transmitted infections & human immunodeficiency virus: 2012 annual report. Edmonton: Government of Alberta; 2014. Available: www.health.alberta.ca/documents/STI-ND-Annual-Report-2012.pdf (accessed 2016 Feb. 17).
35. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
36. Bentley J; Society of Canadian Colposcopists. Colposcopic management of abnormal cervical cytology and histology. J Obstet Gynaecol Can 2012;34:1188-206.